PTC Therapeutics | PTCT - Cash And Equivalent


PTC Therapeutics reported $508.89M in Cash and Equivalent for its fiscal quarter ending in September of 2026.





Cash And Equivalent Change Date
Acadia Pharmaceuticals USD 976.45M 19.97M Sep/2026
Alnylam Pharmaceuticals USD 1.75B 46.02M Sep/2026
Amgen USD 13.19B 799M Sep/2026
BioCryst Pharmaceuticals USD 96.97M 58M Sep/2026
Biogen USD 1.3B 18.9M Sep/2026
BioMarin Pharmaceutical USD 736.01M 138M Sep/2026
Cytokinetics USD 203.43M 51.84M Sep/2026
Daiichi Sankyo JPY 637.85B 188.04B Jun/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Gilead Sciences USD 3.18B 4.45B Jun/2026
Incyte USD 3.85B 127.8M Sep/2026
Ionis Pharmaceuticals USD 296.3M 53.76M Sep/2026
Ironwood Pharmaceuticals USD 86.38M 7.25M Sep/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
Novartis USD 8.87B 1.25B Sep/2026
Pfizer USD 1.82B 848M Sep/2026
PTC Therapeutics USD 508.89M 540.99M Sep/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sarepta Therapeutics USD 472.76M 98.39M Sep/2026
TG Therapeutics USD 429.38M 182.88M Sep/2026
Ultragenyx Pharmaceutical USD 150M 25M Sep/2026
Vertex Pharmaceuticals USD 6.3B 1.55B Sep/2026
Xencor USD 59.62M 14.96M Sep/2026